Restricted Stock and Stock Options	9 Months Ended
Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Restricted Stock and Stock Options	Note 2. Restricted Stock and Stock Options As of September 30, 2021, the Company has two equity incentive plans: the AMERISAFE Non-Employee Director Restricted Stock Plan (the “Restricted Stock Plan”) and the AMERISAFE 2012 Equity and Incentive Compensation Plan (the “2012 Incentive Plan”). See Note 12 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 for additional information regarding the Company’s incentive plans. During the nine months ended September 30, 2021, the Company issued 24,288 shares of common stock pursuant to vested performance awards and 8,707 shares of vested restricted common stock to officers and non-employee directors. The market value of these shares totaled $2.2 million. During the nine months ended September 30, 2020, the Company issued 23,207 shares of common stock pursuant to vested performance awards and 5,269 shares of vested restricted common stock to non-employee directors. The market value of these shares totaled $1.8 million. During the nine months ended September 30, 2021 and 2020, there were no exercises of options to purchase common stock. The Company had no stock options outstanding as of September 30, 2021. The Company recognized share-based compensation expense of $0.4 million in the quarter ended September 30, 2021 and $0.8 million in the same period in 2020. The Company recognized share-based compensation expense of $1.7 million in the nine months ended September 30, 2021 and $2.6 million in the same period in 2020.

Restricted Stock and Stock Options

9 Months Ended

Sep. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Note 2. Restricted Stock and Stock Options

As of September 30, 2021, the Company has two equity incentive plans: the AMERISAFE Non-Employee Director Restricted Stock Plan (the “Restricted Stock Plan”) and the AMERISAFE 2012 Equity and Incentive Compensation Plan (the “2012 Incentive Plan”). See Note 12 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 for additional information regarding the Company’s incentive plans.

During the nine months ended September 30, 2021, the Company issued 24,288 shares of common stock pursuant to vested performance awards and 8,707 shares of vested restricted common stock to officers and non-employee directors. The market value of these shares totaled $2.2 million. During the nine months ended September 30, 2020, the Company issued 23,207 shares of common stock pursuant to vested performance awards and 5,269 shares of vested restricted common stock to non-employee directors. The market value of these shares totaled $1.8 million.

During the nine months ended September 30, 2021 and 2020, there were no exercises of options to purchase common stock. The Company had no stock options outstanding as of September 30, 2021.

The Company recognized share-based compensation expense of $0.4 million in the quarter ended September 30, 2021 and $0.8 million in the same period in 2020. The Company recognized share-based compensation expense of $1.7 million in the nine months ended September 30, 2021 and $2.6 million in the same period in 2020.